Life Sciences Report
Think Like A Brain Surgeon: Dr. Christopher James Offers Fresh Perspectives On 6 Exciting Biotechs
May. 16, 2014
Approval can come much earlier than July 15. I doubt the FDA needs the entire 90 days to come to a decision to approve the product and figure out the final labeling. The FDA does not have unlimited mapower, and it probably wants to move on to other NDAs. I believe the FDA knows where it's going with Afrezza and would like to get this wrapped up quickly
Top Internet Picks for Q4
Given the recent selloff in Internet shares, we believe it is prudent to take a closer look at Internet performance and valuations from a historical context as well as our picks for the remainder of 2013.
We have a positive bias on shares of Google (GOOG), Yahoo (YHOO), Facebook (FB) and believe Amazon. (AMZN) will largely be viewed as a defensive name in the group.
Sarepta's Eteplirsen Walks Closer to Success
By Keith Speights | More Articles | Save For Later
April 5, 2013 |
Sarepta's news related to results from 74 weeks into a phase 2b study of eteplirsen. Patients taking the drug demonstrated continued stabilization of walking ability on the six-minute walk test, a standard assessment of walking capability and clinical function for neuromuscular diseases.
As with earlier points in this study, DMD patients taking eteplirsen showed significant improvement in walking ability compared to patients on placebo. This was true for groups taking the 30 mg/kg and 50 mg/kg dosages of the drug.
Eteplirsen also continued to be well-tolerated. Sarepta reported that no patients experienced significant treatment-related adverse events or any serious adverse events. At week 62, one patient had a temporary elevation of urine protein, but that was resolved and the patient stayed in the study with no further problems.
Chris Garabedian, Sarepta's president and CEO, said that the company was "encouraged to see a continued stabilization of walking ability in patients treated with eteplirsen for nearly one and a half years." Garabedian added that "these results continue to support the potential of eteplirsen t
Renowned Dr. Says will make needles obsolete Read article
Life Sciences Report
Article :Think Like A Brain Surgeon: Dr. Christopher James Offers Fresh Perspectives On 6 Exciting Biotechs
example : india
Is the Market Discounting Galena’s Acquisition of Mills?
Christopher F Davis | More Articles
As I look more at the company, the pipeline of products is captivating. The company is developing innovative targeted oncology therapies that address major unmet needs in the industry to advance cancer treatments.
The company’s leading candidate for a blockbuster product in its pipeline is NeuVax, a vaccine for breast cancer. A very interesting video presentation of the science behind the vaccine can be found here.
jenn mcnary @jennmcnary
told today by max's teacher that he "was running all through the woods" during his field trip to the sugar house "nobody could catch him"
The Street Insider September 23, 2013
Celldex Therapeutics (CLDX) Target Raised to $45 at Leerink Swann
Leerink Swann maintained an Outperform rating on Celldex Therapeutics (NASDAQ: CLDX) and raised its price target to $45.00 (from $28.00). Analyst Howard Liang discussed views on CDX-1127 as an immunotherapy play.
"Ahead of first clinical data on CDX-1127 expected at the Society for Immunotherapy of Cancer (SITC) meeting (Nov. 7-10, National Harbor, MD), we spoke with several MEDACorp key opinion leaders (KOLs) and closely examined available data. Our work enhances our conviction that the potential of immuno-oncology (IO) agents could go far beyond the already impressive data shown so far for PD-1 immune checkpoint inhibitors, and we see an analogy to the HCV space in that the winner may lie in the best combination instead of the best anti-PD1 compound," said Liang.
Great company. Sales Booming.
Consensus Ratings for Intercept Pharmaceuticals (NASDAQ:ICPT)
Ratings Breakdown: 5 Buy Rating(s)Consensus Rating: Buy
Consensus Price Target: $565.00 (38.77% upside)
Mannkind Afrezza FDA Panel Epilogue Plus a Mea Culpa
BY Adam Feuerstein | 04/02/14 - 06:07 AM EDT
NEW YORK (TheStreet) -- Mannkind (MNKD_) By a 13-1 margin, experts on the panel voted to recommend the approval of Afrezza as a new insulin therapy for Type 1 diabetics. The same panel supported Afrezza use in Type 2 diabetics by a 14-0 vote.
Congratulations to Mannkind and its supporters, who were clearly right to believe in Afrezza's approval chances. The panel votes were overwhelmingly positive and should compel the FDA to approve the new in
haled insulin. Mannkind skeptics who believed FDA criticism of Afrezza would persuade the panel to reject the new insulin were wrong. I was one of those Afrezza non-believers, predicting a negative panel vote for both Type 1 and Type 2 diabetes. I was wrong.
covered and long, yes I admit it.
earnings will be over 200% and forward guidance will be off the charts with their new family EV . Have to run to a meeting don't have time to post about guidance on stocktwits, can someone post.
at least $10
Wall Street Journal
Tesla’s Tumble Is a Buying Opportunity